Opioid Agonist Therapy
A new guideline recommends opioid agonist therapy with buprenorphine-naloxone as first-line for the treatment of opioid use disorder.
Slow-Release Oral Morphine, a Promising Opioid Agonist Therapy Alternative to Buprenorphine, MethadoneJanuary 11, 2018
Slow-release oral morphine may be a valuable tool to help reduce the number of deaths from opioid-related overdose.
Immediate access to opioid agonist treatment for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care.
A small fraction of prescriptions for Medicare patients are for opioid agonist therapy, despite higher rates of abuse.
Clinical Pain Advisor Articles
- Reviewing the Efficacy, Safety, and Tolerability of Cannabis-Based Medicines for Chronic Neuropathic Pain
- Femoral Nerve Block Alone or in Combination With Sciatic Nerve Block for TKA: A Meta-Analysis
- Tackling the Chronic Pain and Opioid Use Disorder Crises Through Public-Private Partnerships
- How the City of San Francisco Is Tackling the Intertwined HIV/HCV and Opioid Epidemics
- The State of Drug Storage, Disposal Labeling Information for Opioid Analgesics
- Radiofrequency Ablation for Chronic Hip Pain: Reviewing the Evidence
- Opioid Use Disorder Treatment: Evidence-Based Guideline
- Betel Quid Addiction and Implications for Substance Use Disorder
- Low Back Pain: Contributing Factors, Prophylactic Strategies, and Effective Treatments
- Exparel Approved for Use as Interscalene Brachial Plexus Nerve Block
- Transcranial Magnetic Stimulation May Prevent Migraine in Adolescents
- Widespread Impact of Reducing Opioids, Adding IV Acetaminophen for Postsurgical Pain Management
- GI Safety Compared for NSAIDs in Patients With Arthritis
- Opioid Prescribing Trends in Patients With, Without Cancer
- DOJ Rescinds Protections Afforded by Americans With Disabilities Act